drugset / Trial / NCT00642512
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
RandomizedParallel-groupDouble-blindPrevention
Summary
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring the incidence of total response of nausea and vomiting and/or retching following administration of moderate-to-high emetogenic chemotherapeutic agents.
Timeline
- Start
- 2003-07
- Primary completion
- 2004-07
- Completion
- 2004-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dronabinol | Other / unclassified | 10 mg | — |
| Subject | Dronabinol | Other / unclassified | 20 mg | — |
| Subject | Ondansetron | Other / unclassified | 8 mg | — |
| Subject | Ondansetron | Other / unclassified | 16 mg | — |